No difference in olfactory function between groups was obtained after 12 weeks. Resultsīetween November 2021 and February 2022, we included 115 eligible patients, randomly assigned to the treatment ( n = 58) or placebo group ( n = 57). The CONSORT 2010 guideline was performed. Secondary outcomes were objective gustatory function assessed by the Taste Strip Test (TST) and subjective self-reported outcomes on questionnaires about olfactory, gustatory and trigeminal function, quality of life, and nasal symptoms. The primary outcome was the objective olfactory function on Sniffin’ Sticks Test (SST) 12 weeks after the start of treatment, measured in Threshold-Discrimination-Identification (TDI) score. In addition, all patients performed olfactory training. The treatment group received oral prednisolone 40 mg once daily for 10 days and the placebo group received matching placebo. Patients were included if they were > 18 years old and if they had persistent (> 4 weeks) olfactory disorders within 12 weeks after a confirmed COVID-19 test. We performed a randomized, double-blind, placebo-controlled, single-centered trial in the Netherlands. Hence, we aimed to determine the efficacy of a short oral prednisolone treatment on patients with persistent olfactory disorders after COVID-19. Prednisolone has been suggested as a treatment for olfactory disorders after COVID-19, but evidence is scarce.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |